Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis—multicentre study of 263 Caucasian patients

Author:

Fernández-Díaz Carlos1ORCID,Atienza-Mateo Belén1,Castañeda Santos2,Melero-Gonzalez Rafael B3,Ortiz-SanJuan Francisco4,Loricera Javier1,Casafont-Solé Ivette5,Rodríguez-García Sebastián6,Aguilera-Cros Clara7,Villa-Blanco Ignacio8,Raya-Alvarez Enrique9,Ojeda-García Clara10,Bonilla Gema11,López-Robles Alejandra12,Arboleya Luis13,Narváez Javier14ORCID,Cervantes Evelin15,Maiz Olga16,Alvarez-Rivas María N17,Cabezas Iván18,Salgado Eva19,Hidalgo-Calleja Cristina20,Fernández Sabela21,Fernández Jesús C22,Ferraz-Amaro Ivan23,González-Gay Miguel A1ORCID,Blanco Ricardo1ORCID,

Affiliation:

1. Rheumatology, HU Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain

2. Rheumatology, HU La Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Madrid, UAM, Spain

3. Rheumatology, C.H.U. de Vigo, Vigo, Spain

4. Rheumatology, H.U. La Fe, Valencia, Spain

5. Rheumatology, H.U. Germans Trias i Pujol, Barcelona, Madrid, Spain

6. Rheumatology, H.U. Clinic, Barcelona, Spain

7. Rheumatology, H.U. Virgen del Rocío, Sevilla, Spain

8. Rheumatology, H. Torrelavega, Cantabria, Spain

9. Rheumatology, H.U. San Cecilio, Granada, Spain

10. Rheumatology, H.U. Virgen Macarena, Sevilla, Spain

11. Rheumatology, H.U. La Paz, Madrid, Spain

12. Rheumatology, H.U. León, León, Spain

13. Rheumatology, H.U. Central de Asturias, Asturias, Spain

14. Rheumatology, H.U. Bellvitge, Barcelona, Spain

15. Rheumatology, H.U. de Santiago, Santiago de Compostela, A Coruña, Spain

16. Rheumatology, H.U. Donostia, Donosti, Spain

17. Rheumatology, H.U. Luca Augusti, Lugo, Spain

18. Rheumatology, H.U. Río Hortega, Valladolid, Spain

19. Rheumatology, C.H.U. Ourense, Ourense, Spain

20. Rheumatology, H.U. de Salamanca, Salamanca, Spain

21. Rheumatology, H.U. Cabueñes, Asturias, Spain

22. Rheumatology, C.H.U. A Coruña, Tenerife, Spain

23. Rheumatology, H.U. de Canarias, Tenerife, Spain

Abstract

Abstract Objective To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABAMONO) vs combined ABA [ABA plus MTX (ABAMTX) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABANON-MTX)] in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABAMONO, ABAMTX, ABANON-MTX) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. Results We studied 263 RA-ILD patients (mean ± s.d. age 64.6 ± 10 years) [ABAMONO (n = 111), ABAMTX (n = 46) and ABANON-MTX (n = 106)]. At baseline, ABAMONO patients were older (67 ± 10 years) and took higher prednisone dose [10 (interquartile range 5–15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABAMTX or ABANON-MTX). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. Conclusion In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.

Funder

RETICS Program

European Regional Development Fund

Instituto de Salud Carlos III

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3